Clinical trials: Chronic Schizophrenia
Chronic Schizophrenia
Integrated Psychological Therapy for Chronic Schizophrenia
Background: The chronic phase of schizophrenia (CS) that extremely affects the way people think, feel and act, underlines the need for effective interventions in patients affected by this disorder.
- Trial name
- NCT03275909
- Testing
- Integrated Psychological Therapy
- Volunteers
- 77 people, healthy volunteers welcome
- Sponsor
- University of the Basque Country (UPV/EHU)
Schizophrenia, Schizoaffective Disorder
Safety and Tolerability of BL-1020 in Hospitalized Subjects With Chronic Schizophrenia or Schizo-Affective Disorder
An open-label, multi-center, 6-week, sequential cohort study designed to determine the safety and tolerability of two dose ranges of BL-1020 in hospitalized subjects with chronic schizophrenia or schizo-affective disorder
- Trial name
- NCT00480571
- Testing
- BL-1020, BL 1020 High Dose
- Where
- 2 sites in Israel, Romania
- Volunteers
- 90 people
- Sponsor
- BioLineRx, Ltd.
First Episode Psychosis (FEP)
Self-administered COgnitive Personalized Training in Early Psychosis
The overall objective of SCOPe is to improve early intervention in psychosis by providing an innovative eHealth tool that will enable personalized cognitive training, adapted to the individual's cognitive abilities.
- Trial name
- SCOPe (NCT06634446)
- Testing
- a mobile application for cognitive training, video games
- Where
- France
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier St Anne
Coronary Disease, Myocardial Infarction
Chronical Illness-related Limitations of the Ability to Cope With Rising Temperatures, Third Wave
The CLIMATE-III Observational Study examines to what extent chronically ill patients experience adverse health effects because of heat and whether the patients' specific health behavior, somatosensory amplification, risk and…
- Conditions
- Coronary Disease, Myocardial Infarction, Heart Failure, Arrhythmias, Cardiac
- Trial name
- CLIMATE-III (NCT06890208)
- Testing
- No intervention
- Where
- Germany
- Volunteers
- 176 people
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
Schizophrenia, Schizoaffective Disorder
AIMHI NT Relapse Prevention Trial
A new treatment for indigenous people with mental illness in remote communities has been developed. The study hypothesis is that this new treatment will result in better outcomes for clients and carers than the outcomes of…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Psychoses, Substance Induced, Depression
- Trial name
- NCT00192582
- Testing
- Motivational Interview with care plan and education
- Where
- Australia
- Volunteers
- 90 people
- Sponsor
- Menzies School of Health Research
Acute Pain, Chronic Pain, Widespread
Ketamine's Effect Changes the Cortical Electrophysiological Activity Related to Semantic Affective Dimension of Pain
This is a clinical trial that intend to determine the effects of S-ketamine on event-related potentials associated with semantic affective pain-processing
- Conditions
- Acute Pain, Chronic Pain, Widespread, Schizophrenia
- Trial name
- NCT03915938
- Testing
- Ketamine
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Hospital de Clinicas de Porto Alegre
Schizophrenia, Central Nervous System Diseases
Safety and Cognitive Function Study of EVP-6124 in Patients With Schizophrenia
This study is being conducted to determine the safety and effect on cognitive function of two different doses of an investigational medication, EVP-6124, in individuals with schizophrenia who are on chronic stable atypical…
- Conditions
- Schizophrenia, Central Nervous System Diseases, Cognition
- Trial name
- NCT00968851
- Testing
- EVP-6124
- Where
- 31 sites in United States, Russia and 2 more
- Volunteers
- 317 people
- Sponsor
- FORUM Pharmaceuticals Inc
Schizophrenia Spectrum Disorders
Neurophysiologic Biomarkers for Cognitive Rehabilitation
Cognitive symptoms of schizophrenia interfere with daily life-from managing self-care, to more complex tasks like taking medications and living independently.
- Trial name
- NCT05945602
- Testing
- Neurophysiologic Biomarker Assessments
- Where
- United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development
Schizophrenia, Schizoaffective Disorder
eMove - Dance/Movement Therapy Study
Schizophrenia is a chronic and severe mental disorder affecting 20 million people throughout the world and is the fourth leading cause of disability in the developed world.
- Trial name
- NCT05712928
- Testing
- Dance/movement therapy (eMove)
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Drexel University
Chronic Schizophrenia
Role of Nintendo Wii in Improving Negative Symptoms and Quality of Life in Chronic Schizophrenia
The purpose of this study is to determine whether the use of Nintendo Wii will help improve negative symptoms of Schizophrenia and quality of life of patients with chronic Schizophrenia.
- Trial name
- NCT01761383
- Testing
- Nintendo Wii video console and Nintendo Wii Fit Plus games
- Where
- Canada
- Volunteers
- 5 people
- Sponsor
- Queen's University
Schizophrenia
Ziprasidone for Clozapine- or Olanzapine-Associated Diabetes Mellitus
This study is a six-week, open label trial of the novel antipsychotic agent, ziprasidone, added to a stable dose of clozapine or olanzapine in 40 diabetes mellitus patients, patients with an impaired fasting glucose or insulin…
- Trial name
- NCT00351000
- Testing
- Ziprasidone
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- North Suffolk Mental Health Association
Schizophrenia Disorders
Effect of AQW051 on Cognitive Function in Patients With Chronic Stable Schizophrenia
This PoC study is designed to assess the cognitive effects of doses of AQW051 in patients with chronic stable schizophrenia.
- Trial name
- NCT01163227
- Testing
- AQW051 2 mg (single and multiple doses), AQW051 15mg (single and multiple doses), AQW051 100mg (single dose), and 50mg (multiple doses)
- Where
- 2 sites in United States
- Volunteers
- 57 people
- Sponsor
- Novartis Pharmaceuticals
Schizophrenia, Schizoaffective Disorder
Thinking Skills for Work in Severe Mental Illness
The purpose of this study is help people with serious mental illness and receiving vocational rehabilitation get and keep the job they want by improving their thinking skills, such as attention and memory, using computer…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Major Depression, Bipolar Disorder
- Trial name
- TSW (NCT01926613)
- Testing
- Thinking Skills for Work Program, Supported Employment
- Where
- 2 sites in United States
- Volunteers
- 110 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Schizophrenia, Psychotic Disorder
A Study of the Effectiveness and Safety of Risperidone Compared With Haloperidol in Patients With Chronic Schizophrenia
The purpose of the study is to evaluate the effectiveness and safety of different doses of risperidone (an antipsychotic medication) compared with a fixed 10-mg dose of a standard antipsychotic, haloperidol, in patients with…
- Trial name
- NCT00249119
- Testing
- risperidone
- Volunteers
- 1,579 people
- Sponsor
- Janssen, LP
Schizophrenia
Efficacy and Safety Study of Clozapine Augmented by Atomoxetine Versus Clozapine Augmented by Placebo in Patients With Chronic Resistant Schizophrenia
This is a randomized, placebo-controlled study to assess the efficacy and safety of ATX augmentation of CLZ as a treatment for the cognitive symptoms of schizophrenia.
- Trial name
- NCT00216281
- Where
- United States
- Volunteers
- 126 people
- Sponsor
- Indiana University
Schizophrenias, Psychoses
D-amino Acid Oxidase Inhibition (DAAOI-1) add-on Treatment for Chronic Schizophrenia
Adjuvant N-methyl-D-aspartic acid (NMDA)-enhancing agents, such as GlyT-1 inhibitors and NMDA-glycine site agonists have been demonstrated to be beneficial for chronic schizophrenia patients.
- Conditions
- Schizophrenias, Psychoses, Psychotic Disorders, Schizophrenic Disorders
- Trial name
- NCT00960219
- Testing
- D-amino acid oxidase inhibition (DAAOI-1)
- Where
- Taiwan
- Volunteers
- 52 people
- Sponsor
- China Medical University Hospital
Schizophrenia
A Multicenter Study of NAP (AL-108) in Schizophrenia
The TURNS is a NIMH-funded contract for the evaluation of new compounds for the treatment of cognitive impairments in schizophrenia (HHSN 27820044 1003C; P.I.: Steve Marder, M.D.).
- Trial name
- AL-108 (NCT00505765)
- Testing
- AL-108
- Where
- 8 sites in United States
- Volunteers
- 63 people
- Sponsor
- University of California, Los Angeles
Schizophrenia, Impaired Cognition
A 26-Week Extension Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy
This study is being conducted to further investigate the safety of prolonged exposure to EVP-6124 in subjects with Schizophrenia receiving a stable dose of an atypical antipsychotic who completed double-blind treatment on studies…
- Trial name
- NCT01714713
- Testing
- EVP-6124
- Where
- 128 sites in United States, Argentina and 14 more
- Volunteers
- 830 people
- Sponsor
- FORUM Pharmaceuticals Inc
Schizophrenia
Effectiveness of Aripiprazole Long-acting Injection in Recent Onset and Chronic Schizophrenia Patients
The aim of the study is to investigate the effectiveness of Aripiprazole long-acting injection in recent onset and chronic schizophrenia patients
- Trial name
- NCT03839251
- Testing
- abilify maintena
- Where
- 5 sites in South Korea
- Volunteers
- 82 people
- Sponsor
- Chonbuk National University Hospital
Age-Related Macular Degeneration, Allergies
Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
To collect, preserve, and/or distribute annotated biospecimens and associated medical data to institutionally approved, investigator-directed biomedical research to discover and develop new treatments, diagnostics, and…
- Conditions
- Age-Related Macular Degeneration, Allergies, Alpha-Gal Syndrome, Alzheimer Disease
- Trial name
- NCT05635266
- Testing
- Specimen sample
- Where
- United States
- Volunteers
- 20,000 people, healthy volunteers welcome
- Sponsor
- Sanguine Biosciences